Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Chapter 1 - Preclinical Drug Development: Translating Basic Research into Clinical Work

Modern drug development in oncology relies on the identification of molecular changes that drive the malignant transformation and are responsible for the development and progression of cancer. This is now possible through improvements in our knowledge of the biology of cancer. The development of new cancer therapeutics has been, however, slow and inefficient; as such, alternative strategies are needed. Preclinical studies are important by providing information that is necessary for the subsequent clinical development of any new anti-cancer agent. Data generated from relevant cell lines and xenograft models are crucial to facilitate a better understanding of the agent’s target, mechanism of action, anti-tumour activity against different tumour types, pharmacology, and toxicology, before entering human clinical testing. The use of preclinical models that more closely reflect the biology of human cancer will help to improve the success rate of new anti-cancer compounds. Finally, the discovery of predictive biomarkers of response, their development in preclinical studies, and their subsequent validation in clinical studies will help to define patient populations most likely to benefit from future treatments.

Further Reading

Companion Diagnostics Development Editors and Contributors

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings